Dimensional Fund Advisors LP Acquires 26,143 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Dimensional Fund Advisors LP lifted its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 52.3% in the second quarter, Holdings Channel.com reports. The fund owned 76,086 shares of the biopharmaceutical company’s stock after purchasing an additional 26,143 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Lexicon Pharmaceuticals were worth $128,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LXRX. Principal Financial Group Inc. lifted its holdings in Lexicon Pharmaceuticals by 116.1% during the 2nd quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 12,225 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in Lexicon Pharmaceuticals by 44.5% during the 2nd quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 13,972 shares during the last quarter. Virtu Financial LLC bought a new position in Lexicon Pharmaceuticals during the 1st quarter valued at about $105,000. China Universal Asset Management Co. Ltd. lifted its holdings in Lexicon Pharmaceuticals by 65.7% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 46,930 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 18,601 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Lexicon Pharmaceuticals by 82.6% during the 1st quarter. BNP Paribas Financial Markets now owns 59,378 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 26,859 shares during the last quarter. 74.70% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on LXRX shares. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Thursday, October 3rd. StockNews.com upgraded shares of Lexicon Pharmaceuticals to a “sell” rating in a research report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.50.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX opened at $1.79 on Wednesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 11.49 and a current ratio of 11.51. Lexicon Pharmaceuticals, Inc. has a twelve month low of $0.92 and a twelve month high of $3.73. The firm’s 50 day moving average price is $1.67 and its two-hundred day moving average price is $1.78. The firm has a market cap of $440.76 million, a P/E ratio of -2.16 and a beta of 1.28.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. The business had revenue of $1.65 million for the quarter, compared to analyst estimates of $2.74 million. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative return on equity of 105.38%. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. On average, analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.69 EPS for the current fiscal year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.